Our vision is to become the leading company developing pericyte-directed therapies for vascular and microvascular disease.
Our focus
RougeTx is a biotechnology company focused on targeting pericytes, a critical but underexplored cell type responsible for maintaining vascular structure and function.
Our approach
While many vascular disease therapies address downstream symptoms, our approach targets upstream drivers of vessel instability, enabling the potential for disease modification.
Our platform and lead programme
RougeTx is building on novel discoveries from the research of its scientific co-founders, Professor Franck Lebrin and Dr Jérémy Thalgott at Leiden University Medical Center (LUMC) and has established the periSCOPE Platform to support the development of small-molecule drugs to treat microvascular disease.
Our lead drug programme, RTX-001, is in Hereditary Haemorrhagic Telangiectasia (HHT).
A private company, RougeTx is led by an experienced management team, backed by a strong syndicate of investors
© RougeTx
